Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI608 or BBI503 with Sorafenib in Advanced HCC
NCT02279719Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2014
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of napabucasin, amcasertib in hepatocellular carcinoma (HCC), sponsored by Sumitomo Pharma America. Started Dec 2014; status: completed.
02
Drugs
napabucasinamcasertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02279719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279719.